According to a comprehensive market report authored by DeciBio Consulting LLC, “In Vitro Diagnostic (IVD) Market Report 2025-2030”, the global in vitro diagnostics market is predicted to reach $109B by 2030. This growth will be driven by increasing access to and adoption of diagnostics, the development of new therapies requiring ongoing testing, and the rise of emerging technologies (e.g., computational pathology, liquid biopsy) poised to gain clinical traction and improve patient care.

DeciBio’s IVD report takes an updated and comprehensive look at the IVD landscape. Informed by a combination of primary research from stakeholders across the IVD industry, extensive secondary research, and proprietary DeciBio databases and tools, this report provides a quantitative and qualitative assessment of the key market segments and trends.

IVDs, which have long served as the cornerstone of disease detection and patient monitoring, have a strong influence on every stage of the patient journey. IVD tests enable rapid, accurate assessment of a wide range of conditions, from infectious diseases and cancer to cardiovascular, metabolic, and genetic disorders. Advances in automation, digital pathology, and molecular technologies now allow clinicians to obtain actionable results faster and with higher sensitivity, supporting earlier intervention and more personalized treatment decisions.

This report covers IVD testing spanning across diagnostic modalities and therapeutic areas, providing a detailed assessment of each segment of the market.

Learn more about DeciBio’s In Vitro Diagnostics Market Report: https://www.decibio.com/product/global-in-vitro-diagnostics-market-report-first-edition-2025-2030

In Vitro Diagnostics Companies Profiled:

• Abbott
• Agilent
• Becton Dickinson
• Bio-Rad
• bioMérieux
• Danaher
• Fujirebio
• Hologic
• QIAGEN
• QuidelOrtho
• Revvity
• Roche
• Siemens Healthineers
• Sysmex
• Thermo Fisher

Market Drivers:

The IVD market experienced rapid growth during the COVID-19 pandemic, driven by the global establishment of respiratory testing and surveillance campaigns. Though growth rates have returned to more stable levels witnessed prior to the pandemic, several factors are expected to support expansion in the IVD market. Increasing access to diagnostics globally, driven by the continued development of point-of-care diagnostics and global health initiatives, enables testing in broader patient populations. The number of new therapies requiring ongoing testing across the patient journey drives higher testing rates before, during and after therapeutic treatment. Meanwhile, emerging technologies, such as liquid biopsy assays and digital pathology tools, expand the range of applications for molecular and image-based diagnostics. At the same time, demographic and epidemiologic trends, including an aging population and the rising global burden of chronic diseases, are expected to drive sustained testing across core clinical segments. Together, these forces reinforce the essential role of IVDs in disease prevention, management, and personalized care.

Market Moderators:

The report also highlights key moderators likely to temper growth in the IVD market over the forecasted period. Entrenched customer bases and long-term vendor relationships create high switching costs, limiting opportunities for smaller or newer entrants to gain market share. The widespread perception that existing routine tests are “good enough” for most clinical needs presents a barrier to the adoption of higher-value specialty assays, especially if the use of a specialty assay doesn’t result in a change to patient care. Additionally, persistent downward pressure on reimbursement rates continues to erode margins for both labs and manufacturers, discouraging investment in innovation. Workforce shortages, particularly in laboratory medicine and pathology, further strain testing capacity and slow adoption of new technologies that require specialized expertise. Finally, the poor return on investment often associated with diagnostics relative to therapeutics remains a structural headwind, reinforcing the need for stronger evidence of clinical and economic utility to justify pricing and broader uptake.

About DeciBio:

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating innovation in precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251111660934/en/